Opus Genetics has officially treated the first participant in its Phase 1/2 clinical trial for OPGx-001 — a new gene therapy designed for individuals with LCA5-related Leber congenital amaurosis. This milestone marks the company’s first human trial and represents another important step forward in treating inherited retinal diseases. As more early-stage therapies enter clinical testing, hope continues to grow for families affected by progressive vision loss.

The Foundation Fighting Blindness has released four years of natural history data from its RUSH2A study, giving researchers open access to valuable insights into USH2A-related retinitis pigmentosa and Usher syndrome. This unprecedented data release is expected to accelerate clinical trial development and advance treatments for inherited retinal diseases.

✨ New Hope for XLRP Patients
The SKYLINE Phase 2 trial of laruzova, a gene therapy for X-linked retinitis pigmentosa, has shown promising vision improvements at 24 months. With the pivotal VISTA Phase 3 trial now fully enrolled, this breakthrough research moves us one step closer to potential treatment for this rare inherited blindness.

🚀 Hope for Stargardt Disease
Ocugen has announced FDA clearance to begin a Phase 2/3 trial of OCU410ST, a groundbreaking modifier gene therapy for Stargardt disease. Early results show slowed disease progression and vision improvements, bringing real hope to the 1 million people worldwide affected by this inherited condition.

Scientists have discovered that blocking a protein called Prox1 may allow the eye to repair itself. This breakthrough could open the door to regenerative therapies for vision loss caused by diseases like retinitis pigmentosa.